OpenAI debuts GPT-Rosalind, a new limited access model for life sciences, and broader Codex plugin on Github

Named after the pioneering chemist Rosalind Franklin, whose work was vital to the discovery of DNA’s structure (and was often overlooked for her male colleagues James Watson and Francis Crick), this new frontier reasoning model is purpose-built to act as a specialized intelligence layer for life sciences research.By shifting AI’s role from a general-purpose assistant to a domain-specific reasoning partner, OpenAI is signaling a long-term commitment to biological and chemical discovery. What GPT-Rosalind offersGPT-Rosalind isn't just about faster text generation; it is designed to synthesize evidence, generate biological hypotheses, and plan experiments—tasks that have traditionally required years of expert human synthesis.At its core, GPT-Rosalind is the first in a new series of models optimized for scientific workflows. While previous iterations of GPT excelled at general language tasks, this model is fine-tuned for deeper understanding across genomics, protein engineering, and chemistry.To validate its capabilities, OpenAI tested the model against several industry benchmarks. On BixBench, a metric for real-world bioinformatics and data analysis, GPT-Rosalind achieved leading performance among models with published scores. In more granular testing via LABBench2, the model outperformed GPT-5.4 on six out of eleven tasks, with the most significant gains appearing in CloningQA—a task requiring the end-to-end design of reagents for molecular cloning protocols.The model’s most striking performance signal came from a partnership with Dyno Therapeutics. In an evaluation using unpublished, uncontaminated RNA sequences, GPT-Rosalind was tasked with sequence-to-function prediction and generation. When evaluated directly in the Codex environment, the model’s submissions ranked above the 95th percentile of human experts on prediction tasks and reached the 84th percentile for sequence generation. This level of expertise suggests the model can serve as a high-level collaborator capable of identifying expert-relevant patterns that generalist models often overlook.The new lab workflowOpenAI is not just releasing a model; it is launching an ecosystem designed to integrate with the tools scientists already use. Central to this is a new Life Sciences research plugin for Codex, available on GitHub.Scientific research is famously siloed. A single project might require a researcher to consult a protein structure database, search through 20 years of clinical literature, and then use a separate tool for sequence manipulation. The new plugin acts as an orchestration layer, providing a unified starting point for these multi-step questions.Skill Set: The package includes modular skills for biochemistry, human genetics, functional genomics, and clinical evidence.Connectivity: It connects models to over 50 public multi-omics databases and literature sources.Efficiency: This approach targets long-horizon, tool-heavy scientific workflows, allowing researchers to automate repeatable tasks like protein structure lookups and sequence searches.Limited and gated accessGiven the potential power of a model capable of redesigning biological structures, OpenAI is eschewing a broad open-source or general public release in favor of a Trusted Access program.The model is launching as a research preview specifically for qualified Enterprise customers in the United States. This restricted deployment is built on three core principles: beneficial use, strong governance, and controlled access. Organizations requesting access must undergo a qualification and safety review to ensure they are conducting legitimate research with a clear public benefit.Unlike general-use models, GPT-Rosalind was developed with heightened enterprise-grade security controls. For the end-user, this means:Restricted Access: Usage is limited to approved users within secure, well-managed environments.Governance: Participating organizations must maintain strict misuse-prevention controls and agree to specific life sciences research preview terms.Cost: During the preview phase, the model will not consume existing credits or tokens, allowing researchers to experiment without immediate budgetary constraints (subject to abuse guardrails).Warm reception from initial industry partnersThe announcement garnered significant buy-in from OpenAI parnters across the pharmaceutical and technology sectors. Sean Bruich, SVP of AI and Data at Amgen, noted that the collaboration allows the company to apply advanced tools in ways that could accelerate how we deliver medicines to patients.The impact is also being felt in the specialized tech infrastructure that supports labs:NVIDIA: Kimberly Powell, VP of Healthcare and Life Sciences, described the convergence of domain reasoning and accelerated computing as a way to compress years of traditional RD into immediate, actionable scientific insights.Moderna: CEO Stéphane Bancel highlighted the model's ability to reason across complex biological evidence to help teams translate insights into experimental workflows.The Allen Institute: CTO Andy Hickl emphasized that GPT-Rosalind stands out for making manual steps—like finding and aligning data—more consistent and repeatable in an agentic workflow.This builds on tangible results OpenAI has already seen in the field, such as its collaboration with Ginkgo Bioworks, where AI models helped achieve a 40 reduction in protein production costs.What's next for Rosalind and OpenAI in life sciences?OpenAI’s mission with GPT-Rosalind is to narrow the gap between a promising scientific idea and the actual evidence, experiments, and decisions required for medical progress. By partnering with institutions like Los Alamos National Laboratory to explore AI-guided catalyst design and biological structure modification, the company is positioning GPT-Rosalind as more than a tool—it is meant to be a capable partner in discovery.As the life sciences field becomes increasingly data-dense, the move toward specialized reasoning models like Rosalind may become the standard for navigating the vast search spaces of biology and chemistry.